PMID: 6171545Nov 1, 1981Paper

Combination chemotherapy for advanced squamous cell carcinoma of the head and neck

Head & Neck Surgery
D D CokerJ R Hebel

Abstract

Fifty-one patients (32 previously untreated, 19 previously treated) with advanced squamous cell carcinoma of the head and neck received a single course of combination chemotherapy consisting of high dose cis-platinum (DDP), bleomycin (Bleo), +/- high dose methotrexate (MTX). Thirty-three (65%) patients responded to therapy; 5 (10%) of these patients had a complete response. Previously untreated patients and those who received the three drugs (DDP, Bleo and MTX) had the highest response rates. The duration of response was 8 to 12 weeks. Seven (15%) patients showed a two-year survival rate. All nonresponders were dead of disease within two years. Three (56%) of the five complete-response patients and 4 (21%) of the partial-response patients survived for two years. The role of preoperative chemotherapy in head and neck cancer is yet to be conclusively defined.

References

Mar 1, 1971·British Journal of Cancer·M C Berenbaum
Oct 1, 1971·Journal of Chronic Diseases·B F Hankey, M H Myers

❮ Previous
Next ❯

Citations

Jan 1, 1985·Seminars in Surgical Oncology·F L MoffatJ A Falk
Feb 1, 1983·Clinical Otolaryngology and Allied Sciences·J Hibbert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.